← Back to Search

18F-FDHT PET/MRI for Breast Cancer

Q: What is the total number of individuals participating in this research?

<p>Indeed. According to the information published on clinicaltrials.gov, this experiment is actively recruiting participants with a start date of October 24th 2023 and an end date of November 17th 2023. It requires 10 individuals at 1 medical centre for completion.</p>

Q: Are there any opportunities for volunteers to join this research endeavor?

<p>According to the information provided on clinicaltrials.gov, this experiment is in need of participants. It was initially posted on October 24th 2023 and has been recently updated November 17th that same year.</p>

Phase < 1

Recruiting

Led By Maxine Jochelson, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Histologically confirmed AR+ breast cancer

ECOG performance score of 0-2

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 8 weeks post treatment

Awards & highlights

Study Summary

This trial tests if PET/MRI scans can detect AR-positive breast cancer with accuracy.

Who is the study for?

This trial is for women over 18 with progressive metastatic breast cancer that tests positive for androgen receptors (AR+). They should be planning to receive antiandrogen therapy, have a decent performance status (ECOG 0-2), and not just have CNS disease. Women who are pregnant or breastfeeding, those with MRI unsafe implants, severe allergies to contrast materials, or very limited life expectancy cannot participate.Check my eligibility

What is being tested?

The study is testing the effectiveness of using two types of PET scans - one with a tracer called 18F-FDHT and another with 18F-FDG - in detecting AR-positive breast cancer in women. These scans could help identify if certain treatments targeting the antiandrogen pathway might work.See study design

What are the potential side effects?

Potential side effects from the PET/MRI scans may include reactions to tracers like mild pain or discomfort at injection site. Allergic reactions to contrast material used during MRI can occur but are rare. The scan itself is non-invasive but requires lying still for periods.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My breast cancer is confirmed to be AR positive.

Select...

I am able to care for myself and move around.

Select...

I am 18 years old or older.

Select...

My breast cancer has worsened or spread since my last scan.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 8 weeks post treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~8 weeks post treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks post treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of lesions that correlate 18F-FDHT uptake with IHC expression of AR

Trial Design

1Treatment groups

Experimental Treatment

Group I: Participants with Breast CancerExperimental Treatment3 Interventions

Participants with histologically confirmed AR+ breast cancer

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

18F-FDG PET/CT

2018

N/A

~210

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,936 Previous Clinical Trials

588,888 Total Patients Enrolled

202 Trials studying Breast Cancer

81,093 Patients Enrolled for Breast Cancer

Maxine Jochelson, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

4 Previous Clinical Trials

1,337 Total Patients Enrolled

2 Trials studying Breast Cancer

88 Patients Enrolled for Breast Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the total number of individuals participating in this research?

"Indeed. According to the information published on clinicaltrials.gov, this experiment is actively recruiting participants with a start date of October 24th 2023 and an end date of November 17th 2023. It requires 10 individuals at 1 medical centre for completion."

Answered by AI

Are there any opportunities for volunteers to join this research endeavor?

"According to the information provided on clinicaltrials.gov, this experiment is in need of participants. It was initially posted on October 24th 2023 and has been recently updated November 17th that same year."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer

2023. "A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06145399.

All > Testosterone